The Study Of β1 Receptor Blockers On Lung Function And Tolerance In Patients With Coronary Heart Disease Accompanied By Chronic Obstructive Pulmonary Disease

Objective To investigate the influence of different doses of β1 receptor blockers on lung function in patients with coronary heart disease accompanied by chronic obstructive pulmonary disease, and to study its tolerance.Methods We evaluated the data of 84 patients hospitalized in the Jining First People’s Hospital with a diagnosis of CHD and COPD from February 2014 to August 2015. 84 cases of patients were randomly divided into two groups, 43 in Bisoprolol group and 41 in control group, Bisoprolol group were divided into two groups, group A(Bisoprolol 2.5 mg per morning) and group B(Bisoprolol 5.0 mg per morning). All patients were treated with conventional medical treatment, Bisoprolol group were treated by the routine treatment and Bisoprolol. The patients in the two groups were tested lung function on admission and after 1 month, All patients were followed up 6 months, and the MACE(major adverse cardiac events,acute myocardial infarction, heart failure, again angina) and the re-admission rate were recorded. Data processing and statistical analysis using SPSS19.0 statistical analysis package, the measurement data used t test, the count data used chi-square test. P value less than 0.05 was considered statistically significant.Results 1, The general datas including gender, age, smoking, hypertension, diabetes and the levels of lipid, et al. The lung function tests including Forced expired volume in one second to forced vital capacity ratio(FEV1 / FVC %), Forced expired volume in one second(FEV1) and The first second forced expiratory volume percentage of expected value(FEV1 %). there was no statistical difference(P > 0.05).2, There was no statistical difference on the lung function on admission and after 1 month between group A and control group(P>0.05). There was no statistical difference on the lung function on admission and after 1 month between group B and control group(P>0.05). There was no statistical difference on the lung function on admission and after 1 month between group A and group B(P>0.05).3, During the follow-up period, there were 5 MACE(14.63%) in Bisoprolol group, including 2 cases of angina pectoris(4.65%), 2 cases of acute myocardial infarction(2.33%)and 2 cases of heart failure(4.65%). there were 13 MACE(31.71%) in control group, including 6 cases of angina pectoris(14.63%), 2 cases of acute myocardial infarction(4.88%)and 5 cases of heart failure(12.20%).MACE was significant difference between two groups(P=0.03). There were 2 re-onset patients(4.65%)in Bisoprolol group, There were 9 re-admission patients(21.95%)in control group, The re-admission rate was significant difference between two groups(P=0.02).4, In the follow-up 6 months, Bisoprolol group have 3 adverse reactions(2 fatigue and 1 digestive system adverse reactions).Conclusion1, The different doses of β1 receptor blockers(Bisoprolol)had no significant effects on lung function in patients with CHD and COPD.2, The β1 receptor blockers(Bisoprolol)may reduce the incidence and the re-admission rate of major adverse cardiac events in patients with CHD and COPD.3, The β1 receptor blockers(Bisoprolol)had no adverse reactions in patients with CHD and COPD. Patients had a good tolerance.